Synthesis and preclinical evaluation of BOLD-100 radiolabeled with ruthenium-97 and ruthenium-103
Dalton Transactions · 2024 · 53 (13) · 6031-6040
DOI: 10.1039/d4dt00118d ↗Kurz gefasst
Fachartikel in der Zeitschrift Dalton Transactions, 2024. Verfasst von B Happl und 15 weiteren Autor:innen. Beteiligte Einrichtung: Ludwig Boltzmann Institute Applied Diagnostics, General Hospital of Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria. thomas.mindt@univie.ac.at. Hauptthemen laut MEDLINE: Antineoplastic Agents, Neoplasms, Ruthenium, Organometallic Compounds. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0). Gefördert von: Institut National des Sciences de l'Univers, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Conseil Régional des Pays de la Loire.
Abstract (Originalsprache)
Radiolabeling of the chemotherapeutic agent BOLD-100 with ruthenium-103 enables animal experiments with lower amounts of injected drug. This leads to a relatively higher tumor uptake and promising tumor-to-background ratio for future imaging studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Ludwig Boltzmann Institute Applied Diagnostics, General Hospital of Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria. thomas.mindt@univie.ac.at.
- Division of Nuclear Medicine, Department of Biomedical Imaging and Image Guided Therapy, Medical University of Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria.
- Institute of Inorganic Chemistry, Faculty of Chemistry, University of Vienna, Josef-Holaubek-Platz 2 and Währinger Straße 42, 1090 Vienna, Austria.
- Joint Applied Medicinal Radiochemistry Facility of the University of Vienna and the Medical University of Vienna, Vienna, Austria.
- Center for Cancer Research and Comprehensive Cancer Center, Medical University of Vienna, Borschkegasse 8A, 1090 Vienna, Austria.
- Research cluster "Translational Cancer Therapy Research", Währinger Straße 42, 1090 Vienna, Austria.
Förderung
- Institut National des Sciences de l'Univers, Centre National de la Recherche Scientifique
- Institut National de la Santé et de la Recherche Médicale
- Conseil Régional des Pays de la Loire
- European Commission
Zitieren
APA
Happl, B., Balber, T., Heffeter, P., Denk, C., Welch, J. M., Köster, U., Alliot, C., Bonraisin, A. C., Brandt, M., Haddad, F., Sterba, J. H., Kandioller, W., Mitterhauser, M., Hacker, M., Keppler, B. K., & Mindt, T. L. (2024). Synthesis and preclinical evaluation of BOLD-100 radiolabeled with ruthenium-97 and ruthenium-103. Dalton Transactions, 53(13), 6031-6040. https://doi.org/10.1039/d4dt00118d
Vancouver
Happl B, Balber T, Heffeter P, Denk C, Welch JM, Köster U, et al. Synthesis and preclinical evaluation of BOLD-100 radiolabeled with ruthenium-97 and ruthenium-103. Dalton Transactions. 2024;53(13):6031-6040. doi:10.1039/d4dt00118d
BibTeX
@article{Happl2024,
author = {Happl, B and Balber, T and Heffeter, P and Denk, C and Welch, J M and Köster, U and Alliot, C and Bonraisin, A-C and Brandt, M and Haddad, F and Sterba, J H and Kandioller, W and Mitterhauser, M and Hacker, M and Keppler, B K and Mindt, T L},
title = {Synthesis and preclinical evaluation of BOLD-100 radiolabeled with ruthenium-97 and ruthenium-103},
journal = {Dalton Transactions},
year = {2024},
volume = {53},
number = {13},
pages = {6031--6040},
doi = {10.1039/d4dt00118d}
}
EUVIMED